Redhawk Wealth Advisors Inc. Takes $1.27 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Redhawk Wealth Advisors Inc. bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 61,009 shares of the biopharmaceutical company's stock, valued at approximately $1,273,000. Redhawk Wealth Advisors Inc. owned 0.05% of Catalyst Pharmaceuticals as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Dimensional Fund Advisors LP lifted its position in Catalyst Pharmaceuticals by 9.6% during the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company's stock worth $46,479,000 after acquiring an additional 263,099 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company's stock worth $45,968,000 after purchasing an additional 2,965,310 shares during the period. Renaissance Technologies LLC lifted its holdings in Catalyst Pharmaceuticals by 15.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company's stock worth $33,702,000 after purchasing an additional 287,300 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Catalyst Pharmaceuticals by 4.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company's stock valued at $23,215,000 after purchasing an additional 50,804 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in Catalyst Pharmaceuticals by 47.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 618,296 shares of the biopharmaceutical company's stock valued at $9,577,000 after buying an additional 200,370 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Catalyst Pharmaceuticals

In related news, Director Molly Harper sold 17,500 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Steve Miller sold 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares in the company, valued at $15,065,822.28. This represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $1,754,140 over the last ninety days. 11.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Bank of America reissued a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Truist Financial increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, November 11th. StockNews.com downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, January 11th. HC Wainwright raised their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, January 10th. Finally, Stephens started coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an "overweight" rating and a $35.00 price objective for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $32.86.

Catalyst Pharmaceuticals Trading Down 1.7 %

NASDAQ CPRX traded down $0.40 on Thursday, hitting $22.66. 1,591,991 shares of the company's stock were exchanged, compared to its average volume of 1,606,504. The stock has a 50-day moving average of $21.78 and a 200-day moving average of $20.15. The stock has a market cap of $2.70 billion, a price-to-earnings ratio of 19.20, a P/E/G ratio of 2.16 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 52 week low of $13.12 and a 52 week high of $24.27.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.